Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• Tumor suppressor in lung cancer 1 (TSLC1) alters tumorigenic growth properties and gene expression.

  PMID 16083501 · PMC1208945 · Molecular cancer · 2005 · 8 claims · 8 setups

  Full-text index only

  Restoration of TSLC1 expression in A549 cells (yielding the 12.2 line) suppresses tumorigenic growth, markedly reducing cell expansion/proliferation rate.

  a549 nsclc expansion wst-1 flow

• ASO-based PKM splice-switching therapy increases anti-CTLA-4 antibody efficacy in pancreatic ductal adenocarcinoma.

  PMID 42009652 · PMC13096517 · Cell discovery · 2026 · 8 claims · 8 setups

  Full-text index only

  PKM2 is upregulated and PKM1 is downregulated in human and murine PDAC tumors relative to normal pancreas

  pdac ntconv bxpc-3 ihc expression 18f-fdg

• IMIREG: a lineage-resolved regulon signature unveiling immune engagement archetypes and predicting immunotherapy response across diverse cancers.

  PMID 42092126 · PMC13234301 · NPJ precision oncology · 2026 · 8 claims · 8 setups

  Full-text index only

  IMIREG, a 14-regulon transcriptional signature, robustly predicts clinical benefit from ICB across 50 immunotherapy cohorts (52 treatment arms) spanning 16 cancer types with mean AUROC = 0.71

  imvigor210 matched gtex healthy bulk scrna-seq pathway

• Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome.

  PMID 41956098 · PMC7619149 · Immunity · 2026 · 8 claims · 8 setups

  Full-text index only

  Reduced NMD activity (lower NMD score) predicts improved CPI response across >1,000 patients, independent of TMB or tumor type

  tcga a375 reporter patient-derived multi-omics crispr-cas9 sirna